Visit COVID-19 resources

[Skip to Content]

Age-related macular degeneration

New Guidance for Commissioning Age Related Macular Degeneration Services

The Royal College of Ophthalmologists (RCOphth) has developed Age Related Macular Degeneration Commissioning Guidance June 2021. The National Institute for Health and Care Excellence (NICE) has  accredited the process used by The Royal College of Ophthalmologists to develop this guidance. It sets out the  principles and minimum standards of care for AMD to decrease variations

National Ophthalmology Database Funding boost for new UK AMD Audit

The Royal College of Ophthalmologists (RCOphth) is delighted to announce that the National Ophthalmology Database (NOD) Audit: Age-Related Macular Degeneration has now received funding for three years, enabling this important programme of long-term research and data gathering to begin. Age-related macular degeneration (AMD) remains a leading cause of sight impairment despite new treatment options. It

Clinical Guidelines

RCOphth Clinical Guidelines The aim of College Clinical Guidelines is to identify the best medical evidence, set standards of patient care and ensure patient safety, providing a benchmark for outcomes within which high quality Ophthalmology can be practiced in the UK health service. Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare

Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative (“wet”) form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is